Grants and Giving
Alnylam Pharmaceuticals funds educational initiatives to improve clinical decision-making and patient care in transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM).
Funder: Alnylam Pharmaceuticals
Due Dates: May 29, 2026 (Submission deadline for RFP ALNY-RFP-TTR-13)
Funding Amounts: Up to $250,000 per proposal; multiple proposals may be funded; single or multiple venues/channels possible.
Summary: Supports independent educational initiatives to improve clinical decision-making and patient outcomes in transthyretin-mediated amyloidosis (ATTR-CM).
Key Information: Only accredited organizations may apply; individuals and certain healthcare entities are ineligible.
Description
Alnylam Pharmaceuticals invites proposals for independent medical education activities aimed at advancing clinical decision-making in transthyretin-mediated amyloidosis with cardiomyopathy (ATTR-CM). This RFP (ALNY-RFP-TTR-13) seeks to fund programs that address critical gaps in screening, diagnosis, monitoring, and management of ATTR, with an emphasis on translating evidence into practical, real-world clinical application. Educational activities should be evidence-based, clinically relevant, and designed to support improved patient care by equipping healthcare professionals with actionable tools and frameworks.
Programs may include symposia at major cardiology congresses, digital CME platforms, live regional events, or other venues targeting relevant specialists (e.g., cardiologists, cardiac imaging specialists, clinical pharmacists). Proposals should include comprehensive gap analyses, SMART learning objectives, robust evaluation plans, and strategies for broad dissemination and sustainability.
